Efficacy and Safety Evaluation of Recombinant Human Growth Hormone (r-hGH), Saizen®, on a Population of Children With Hypochondroplasia, Treated at Least 3 Years or Until Near Final Height, When Applicable, in Comparison With a Historic Cohort of Non-treated Children

Clinical trial NCT01111019 · COMPLETED

Trial details

NCT number

NCT01111019

Sponsor

Merck KGaA, Darmstadt, Germany

Status

COMPLETED

Phase

Phase 2

Study type

INTERVENTIONAL

Start date

2006-03-21

Primary completion

2017-01-17

Enrollment

19

View on ClinicalTrials.gov